Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease
- 610 Downloads
Purpose of review
Therapeutic drug monitoring (TDM) is increasingly utilized as a strategy to optimize inflammatory bowel disease (IBD) therapeutics. As management paradigms have evolved towards treat-to-target strategies, there has been growing interest in expanding the role of TDM to guide drug optimization for achieving objective endpoints. This review summarizes the evidence for using TDM with biologic and oral small-molecule therapies, evaluates the role of reactive versus proactive TDM in treatment algorithms, and identifies potential future applications for TDM.
Achieving therapeutic drug concentrations has been associated with important clinical, endoscopic, and histologic outcomes in IBD. However, the optimal drug concentration varies by therapeutic agent, disease phenotype, inflammatory burden, phase of treatment, and target outcome. Traditionally, TDM has been used reactively to define pharmacokinetic versus mechanistic failures after loss of response to a tumor necrosis factor-α (TNF) antagonist and while observational data suggests a benefit to proactive TDM, this has not been definitively confirmed in prospective randomized controlled trials. The role of TDM in optimizing vedolizumab, ustekinumab, and tofacitinib remains unclear, given differences in pharmacokinetics and immunogenicity compared to TNF antagonists. Measuring drug action at the site of inflamed tissue may provide additional insights into treatment optimization.
The use of TDM offers the possibility of a more personalized treatment approach for patients with IBD. High-quality studies are needed to delineate the role of proactive TDM for maintaining remission, for optimizing induction regimens, and for novel agents.
KeywordsBiologics Crohn’s disease Inflammatory bowel disease Therapeutic drug monitoring Thiopurines Ulcerative colitis
American Gastroenterological Association
body mass index
Crohn’s Disease Activity Index
dose intensification strategy
enzyme-linked immunosorbent assay
homogeneous mobility shift assay
inflammatory bowel disease
reporter gene assay
receiver operating characteristic
therapeutic drug monitoring
tumor necrosis factor
CM, RB, VJ, and, NVC contributed to the study design, manuscript drafting, and manuscript editing. All authors approve the final version of the manuscript.
Dr. Christopher Ma is supported by a Clinician Fellowship from the Canadian Institutes of Health Research and the Canadian Association of Gastroenterology. Dr. Niels Vande Casteele is supported by a Research Scholar Award from the American Gastroenterological Association.
Compliance with Ethical Standards
Conflict of Interest
Christopher Ma and Robert Battat have no conflicts of interest to declare.
Vipul Jairath has received consulting fees from AbbVie, Eli Lilly, GlaxoSmithKline, Arena pharmaceuticals, Genetech, Pendopharm, Sandoz, Merck, Takeda, Janssen, Robarts Clinical Trials, Topivert, and Celltrion, and speaker’s fees from Takeda, Janssen, Shire, Ferring, Abbvie, and Pfizer.
Niels Vande Casteele has received grant/research support from R-Biopharm and Takeda, and consulting fees from Pfizer, Progenity, Prometheus, and Takeda.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Van Assche G. Optimizing biologic therapy for treatment of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2013;9(7):462–4.Google Scholar
- 9.Grossberg LB, Papamichael K, Feuerstein JD, Siegel CA, Ullman TA, Cheifetz AS. A survey study of gastroenterologists’ attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2017;24(1):191–7. https://doi.org/10.1093/ibd/izx023.CrossRefPubMedGoogle Scholar
- 10.•• Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Clinical Guidelines C. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology. 2017;153(3):827–34. https://doi.org/10.1053/j.gastro.2017.07.032 Clinical guidelines from the American Gastroenterological Association for use of therapeutic drug monitoring.CrossRefPubMedGoogle Scholar
- 12.Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology. 2017;153(3):835–57 e6. https://doi.org/10.1053/j.gastro.2017.07.031.CrossRefPubMedGoogle Scholar
- 15.Hutmacher MM, Papp K, Krishnaswami S, Ito K, Tan H, Wolk R, et al. Evaluating dosage optimality for tofacitinib, an oral Janus kinase inhibitor, in plaque psoriasis, and the influence of body weight. CPT Pharmacometrics Syst Pharmacol. 2017;6(5):322–30. https://doi.org/10.1002/psp4.12182.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Mukherjee A, Hazra A, Smith MK, Martin SW, Mould DR, Su C, et al. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: results from a dose-ranging phase 2 trial. Br J Clin Pharmacol. 2018;84(6):1136–45. https://doi.org/10.1111/bcp.13523.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Marini JC, Sendecki J, Cornillie F, Popp JW Jr, Black S, Blank M, et al. Comparisons of serum infliximab and antibodies-to-infliximab tests used in inflammatory bowel disease clinical trials of Remicade(R). AAPS J. 2017;19(1):161–71. https://doi.org/10.1208/s12248-016-9981-3.CrossRefPubMedGoogle Scholar
- 21.Martin S, del Agua AR, Torres N, Pascual-Salcedo D, Plasencia C, Ruiz-Arguello B, et al. Comparison study of two commercially available methods for the determination of golimumab and anti-golimumab antibody levels in patients with rheumatic diseases. Clin Chem Lab Med. 2015;53(11):e297–9. https://doi.org/10.1515/cclm-2015-0266.CrossRefPubMedGoogle Scholar
- 22.Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn’s disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol. 2014;109(7):1055–64. https://doi.org/10.1038/ajg.2014.106.CrossRefPubMedGoogle Scholar
- 23.Bodini G, Giannini EG, Furnari M, Marabotto E, Baldissarro I, Del Nero L, et al. Comparison of two different techniques to assess adalimumab trough levels in patients with Crohn’s disease. J Gastrointestin Liver Dis. 2015;24(4):451–6. https://doi.org/10.15403/jgld.2014.1121.244.adb.CrossRefPubMedGoogle Scholar
- 24.Marini JC, Gils A, Shankar G, Peeters M, Brouwers E, van Iperen P, et al. P649 Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R & D and used in clinical studies of IBD patients. J Crohn's Colitis. 2018;12(supplement_1):S439. https://doi.org/10.1093/ecco-jcc/jjx180.776.CrossRefGoogle Scholar
- 27.Afonso J, Lopes S, Goncalves R, Caldeira P, Lago P, Tavares de Sousa H, et al. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther. 2016;44(7):684–92. https://doi.org/10.1111/apt.13757.CrossRefPubMedGoogle Scholar
- 29.Cornillie F, Hanauer SB, Diamond RH, Wang J, Tang KL, Xu Z, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63(11):1721–7. https://doi.org/10.1136/gutjnl-2012-304094.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.• Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147(6):1296–307 e5. https://doi.org/10.1053/j.gastro.2014.08.035 This analysis of data from the ACT-1 and ACT-2 trials demonstrated that serum infliximab concentrations are associated with treatment efficacy.CrossRefPubMedGoogle Scholar
- 33.Vande Casteele N, Feagan BG, Vermeire S, Yassine M, Coarse J, Kosutic G, et al. Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease. Aliment Pharmacol Ther. 2018;47(2):229–37. https://doi.org/10.1111/apt.14421.CrossRefPubMedGoogle Scholar
- 34.Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, et al. Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2/3 PURSUIT induction and maintenance studies. J Crohns Colitis. 2017;11(1):35–46. https://doi.org/10.1093/ecco-jcc/jjw133.CrossRefPubMedGoogle Scholar
- 35.Brandse JF, Mould D, Smeekes O, Ashruf Y, Kuin S, Strik A, et al. A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):650–60. https://doi.org/10.1097/MIB.0000000000001043.CrossRefPubMedGoogle Scholar
- 36.Steenholdt C, Frederiksen MT, Bendtzen K, Ainsworth MA, Thomsen OO, Brynskov J. Time course and clinical implications of development of antibodies against adalimumab in patients with inflammatory bowel disease. J Clin Gastroenterol. 2016;50(6):483–9. https://doi.org/10.1097/MCG.0000000000000375.CrossRefPubMedGoogle Scholar
- 38.Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–38. https://doi.org/10.1038/ajg.2015.233.CrossRefPubMedGoogle Scholar
- 39.Ungar B, Levy I, Yavne Y, Yavzori M, Picard O, Fudim E, et al. Optimizing anti-TNF-alpha therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14(4):550–7. https://doi.org/10.1016/j.cgh.2015.10.025.CrossRefPubMedGoogle Scholar
- 40.Yarur AJ, Jain A, Hauenstein SI, Quintero MA, Barkin JS, Deshpande AR, et al. Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2016;22(2):409–15. https://doi.org/10.1097/MIB.0000000000000689.CrossRefPubMedGoogle Scholar
- 41.Plevris N, Lyons M, Jenkinson PW, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho GT, Noble CL, Shand AG, Din S, Arnott ID, Jones GR, Lees CW Higher adalimumab drug levels during maintenance therapy for Crohn’s disease are associated with biologic remission. Inflamm Bowel Dis 2018. https://doi.org/10.1093/ibd/izy320.
- 43.Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT. Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn’s disease. Inflamm Bowel Dis. 2018;24(10):2266–71. https://doi.org/10.1093/ibd/izy132.CrossRefPubMedGoogle Scholar
- 44.Vande Casteele N, Jeyarajah J, Jairath V, Feagan BG, Sandborn WJ. Infliximab exposure-response relationship and thresholds associated with endoscopic healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2018. https://doi.org/10.1016/j.cgh.2018.10.036.
- 45.• Yarur AJ, Kanagala V, Stein DJ, Czul F, Quintero MA, Agrawal D, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017;45(7):933–40. https://doi.org/10.1111/apt.13970 This cross-sectional study suggests that higher trough levels may be required for patients with fistulizing CD.CrossRefPubMedGoogle Scholar
- 46.Papamichael K, Vande Casteele N, Ferrante M, Gils A, Cheifetz AS. Therapeutic drug monitoring during induction of anti-tumor necrosis factor therapy in inflammatory bowel disease: defining a therapeutic drug window. Inflamm Bowel Dis. 2017;23(9):1510–5. https://doi.org/10.1097/MIB.0000000000001231.CrossRefPubMedGoogle Scholar
- 47.Baert F, Vande Casteele N, Tops S, Noman M, Van Assche G, Rutgeerts P, et al. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment Pharmacol Ther. 2014;40(11–12):1324–32. https://doi.org/10.1111/apt.12968.CrossRefPubMedGoogle Scholar
- 48.Papamichael K, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14(4):543–9. https://doi.org/10.1016/j.cgh.2015.11.014.CrossRefPubMedGoogle Scholar
- 51.Brandse JF, van den Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149(2):350–5 e2. https://doi.org/10.1053/j.gastro.2015.04.016.CrossRefPubMedGoogle Scholar
- 52.Brandse JF, Mathot RA, van der Kleij D, Rispens T, Ashruf Y, Jansen JM, et al. Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14(2):251–8. https://doi.org/10.1016/j.cgh.2015.10.029.CrossRefPubMedGoogle Scholar
- 53.Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(5):1133–9. https://doi.org/10.1038/ajg.2010.9.CrossRefPubMedGoogle Scholar
- 54.Steenholdt C, Brynskov J, Thomsen OO, Munck LK, Fallingborg J, Christensen LA, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63(6):919–27. https://doi.org/10.1136/gutjnl-2013-305279.CrossRefPubMedGoogle Scholar
- 55.Guidi L, Pugliese D, Panici Tonucci T, Berrino A, Tolusso B, Basile M et al. Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. J Crohns Colitis. 2018. https://doi.org/10.1093/ecco-jcc/jjy076.
- 56.Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13(3):522–30 e2. https://doi.org/10.1016/j.cgh.2014.07.029.CrossRefPubMedGoogle Scholar
- 57.Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol. 2017;15(10):1580–8 e3. https://doi.org/10.1016/j.cgh.2017.03.031.CrossRefPubMedPubMedCentralGoogle Scholar
- 59.Panaccione R, Ghosh S, Middleton S, Marquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400. https://doi.org/10.1053/j.gastro.2013.10.052.CrossRefPubMedGoogle Scholar
- 60.Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25. https://doi.org/10.1016/S0140-6736(09)61302-7.CrossRefPubMedGoogle Scholar
- 62.Colombel JF, Adedokun OJ, Gasink C, Tang KL, Cornillie F, D'Haens GR, et al. Higher levels of infliximab may alleviate the need of azathioprine comedication in the treatment of patients with Crohn’s disease: a sonic post HOC analysis. Gastroenterology. 2017;152(5):S37–S8. https://doi.org/10.1016/S0016-5085(17)30490-0.CrossRefGoogle Scholar
- 63.•• Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–9. https://doi.org/10.1053/j.gastro.2015.02.031 TAXIT Trial: this prospective randomized trial did not demonstrate that concentration-based dosing of infliximab to trough concentrations of 3-7 μg/mL was associated with improved 1-year clinical remission.CrossRefPubMedGoogle Scholar
- 64.Pouillon L, Ferrante M, Van Assche G, Rutgeerts P, Noman M, Sabino J, et al. Mucosal healing and long-term outcomes of patients with inflammatory bowel diseases receiving clinic-based vs trough concentration-based dosing of infliximab. Clin Gastroenterol Hepatol. 2018;16(8):1276–83 e1. https://doi.org/10.1016/j.cgh.2017.11.046.CrossRefPubMedGoogle Scholar
- 65.•• D’Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn’s disease. Gastroenterology. 2018;154(5):1343–51 e1. https://doi.org/10.1053/j.gastro.2018.01.004 TAILORIX Trial: this double-blind randomized trial of patients with active CD did not demonstrate that increasing infliximab dosing by symptoms, biomarkers, and TDM improved clinical remission.CrossRefPubMedGoogle Scholar
- 66.Papamichael K, Osterman MT, Siegel CA, Melmed GY, Dubinsky MC, Colombel JF, et al. Using proactive therapeutic drug monitoring of anti-tumor necrosis factor therapy in inflammatory bowel disease: from an old concept to a future standard of care? Gastroenterology. 2018;154(4):1201–2. https://doi.org/10.1053/j.gastro.2018.01.001.CrossRefPubMedGoogle Scholar
- 67.•• Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11-12):1037–53. https://doi.org/10.1111/apt.14368 Consensus recommendations for use of TDM from the Australian Inflammatory Bowel Diseases Consensus Working Group.CrossRefPubMedGoogle Scholar
- 73.Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther. 2015;42(2):188–202. https://doi.org/10.1111/apt.13243.CrossRefPubMedPubMedCentralGoogle Scholar
- 74.Kotze PG, Ma C, Almutairdi A, Al-Darmaki A, Devlin SM, Kaplan GG, et al. Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48(6):626–37. https://doi.org/10.1111/apt.14919.CrossRefPubMedGoogle Scholar
- 76.Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, et al. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2017;15(9):1427–34 e2. https://doi.org/10.1016/j.cgh.2017.03.032.CrossRefPubMedGoogle Scholar
- 77.Yarur AJ, Jain A, Sussman DA, Barkin JS, Quintero MA, Princen F, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65(2):249–55. https://doi.org/10.1136/gutjnl-2014-308099.CrossRefPubMedGoogle Scholar
- 78.Yoshihara T, Shinzaki S, Kawai S, Fujii H, Iwatani S, Yamaguchi T, et al. Tissue drug concentrations of anti-tumor necrosis factor agents are associated with the long-term outcome of patients with Crohn’s disease. Inflamm Bowel Dis. 2017;23(12):2172–9. https://doi.org/10.1097/MIB.0000000000001260.CrossRefPubMedGoogle Scholar
- 79.Sandborn WJ, Bressler B, Lee S, Bhandari R, Kanwar B, Tozzi L et al. PTG-100, an oral gut-restricted peptide α4β7 antagonist, induces clinical and histologic remission in patients with moderate to severely active ulcerative colitis. United Eur Gastroenterol J. Presented at UEG Week 2018 in Vienna, Austria, 2018;6(Supplement 1).Google Scholar
- 80.Sandborn WJ, Bhandari R, Leighton JA, Ganeshappa R, Nguyen D, Ferslew B et al. The intestinally restricted, orally administered, pan-JAK inhibitor TD-1473 demonstrates favorable safety, tolerability, pharmacokinetics, and signal for clinical activity in subjects with moderately-to-severely active ulcerative colitis. United Eur Gastroenterol J. Presented at UEG Week 2018 in Vienna, Austria, 2018;6(Supplement 1).Google Scholar